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Maladaptive repair contributes towards the development of heart failure 






mediator and determinant of cardiac repair. We aimed to establish whether 




18F-Fluciclatide (a novel αvβ3-selective radiotracer) positron emission 
tomography (PET) and computed tomography (CT) imaging, and 
gadolinium-enhanced magnetic resonance imaging (CMR) were performed 
in 21 patients 2-weeks after ST-segment elevation MI (anterior,n=16; 
lateral,n=4; inferior,n=1). Cardiac CMR was repeated 9 months after MI. 
Seven stable patients with chronic total occlusion (CTO) of a major 





18F-Fluciclatide uptake was increased at sites of acute infarction compared 
to remote myocardium (tissue-to-background ratio (TBRmean) 1.34±0.22 
vs 0.85±0.17; p<0.001) and myocardium of healthy volunteers (TBRmean 
1.34±0.22 vs 0.70±0.03; p<0.001). There was no 18F-fluciclatide uptake 
at sites of established prior infarction in CTO patients, with activity similar 
to the myocardium of healthy volunteers (TBRmean 0.71±0.06 vs. 
0.70±0.03, p=0.83). 18F-Fluciclatide uptake occurred at sites of regional 
wall hypokinesia (wall motion index ≥1 vs 0; TBRmean 0.93±0.31 vs 
0.80±0.26 respectively, p<0.001) and subendocardial infarction. 
Importantly, although there was no correlation with infarct size (r=0.03, 
p=0.90) or inflammation (C-reactive protein, r=-0.20, p=0.38), 18F-
fluciclatide uptake was increased in segments displaying functional 
recovery (TBRmean 0.95±0.33 vs 0.81±0.27, p=0.002) and associated 




18F-Fluciclatide uptake is increased at sites of recent MI acting as a 
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Maladaptive repair contributes towards the development of heart failure 
following myocardial infarction (MI). The αvβ3 integrin receptor is a key 
mediator and determinant of cardiac repair. We aimed to establish whether 
αvβ3 integrin expression determines myocardial recovery following MI. 
Methods 
18F-Fluciclatide (a novel αvβ3-selective radiotracer) positron emission 
tomography (PET) and computed tomography (CT) imaging, and gadolinium-
enhanced magnetic resonance imaging (CMR) were performed in 21 patients 
2 weeks after ST-segment elevation MI (anterior,n=16; lateral,n=4; 
inferior,n=1). Cardiac CMR was repeated 9 months after MI. Seven stable 
patients with chronic total occlusion (CTO) of a major coronary vessel, and 9 
healthy volunteers underwent a single PET/CT and CMR. 
Results 
 
18F-Fluciclatide uptake was increased at sites of acute infarction compared to 
remote myocardium (tissue-to-background ratio (TBRmean) 1.34±0.22 vs 
0.85±0.17; p<0.001) and myocardium of healthy volunteers (TBRmean 
1.34±0.22 vs 0.70±0.03; p<0.001). There was no 18F-fluciclatide uptake at 
sites of established prior infarction in CTO patients, with activity similar to the 
myocardium of healthy volunteers (TBRmean 0.71±0.06 vs. 0.70±0.03, p=0.83). 
18F-Fluciclatide uptake occurred at sites of regional wall hypokinesia (wall 
motion index ≥1 vs 0; TBRmean 0.93±0.31 vs 0.80±0.26 respectively, p<0.001) 
and subendocardial infarction. Importantly, although there was no correlation 



































































with infarct size (r=0.03, p=0.90) or inflammation (C-reactive protein, r=-0.20, 
p=0.38), 18F-fluciclatide uptake was increased in segments displaying 
functional recovery (TBRmean 0.95±0.33 vs 0.81±0.27, p=0.002) and 
associated with increase in probability of regional recovery.  
Conclusions 
18F-Fluciclatide uptake is increased at sites of recent MI acting as a 










































































What is already known about this subject? 
Non-invasive imaging of myocardial remodeling may permit understanding, 
prediction and potential modification of adverse remodeling and the syndrome 
of delayed heart failure following MI. The αvβ3 integrin cell surface receptor is 
intrinsic to angiogenesis, inflammation and fibrogenesis in remodeling 
myocardium and has been targeted using positron emission tomography 
(PET) radiotracers in murine and small human studies following MI. However, 
the role of αvβ3 integrin radiotracers in humans following MI is incompletely 
defined.  
 
What does this study add? 
Using PET imaging with kinetic analysis, computed tomography (CT) contrast 
angiography and cardiac magnetic resonance imaging we have demonstrated 
18F-fluciclatide binding with αvβ3 integrin receptors in regions of acute 
myocardial infarction and in the remote myocardium. 18F-fluciclatide uptake 
correlates with functional impairment and may predict myocardial recovery.  
 
How might this impact on clinical practice? 
Our study fulfils a key step validating αvβ3 integrin receptor imaging in humans 
following MI. This novel characterisation of myocardial remodeling may hold 
potential as a biological end-point in the study of novel therapies following MI.  
  





































































Ischemic heart disease remains the leading cause of death globally, with over 
1 million people suffering acute myocardial infarction (MI) per year in the USA 
alone.  As the acute management of MI improves, the number of patients 
surviving acute myocardial injury is higher than ever before. In this population, 
adverse cardiac remodeling and the syndrome of delayed heart failure 
represents a major cause of morbidity.[1] Understanding reparative 
mechanisms following infarction is becoming increasingly important. 
 
Repair following MI is triggered by a complex interaction of neurohormonal 
activation and up-regulation of angiogenic and pro-fibrotic transcription factors 
that initiate the restoration of a capillary network through angiogenesis and re-
endothelialization, as well as extracellular matrix (ECM) remodeling through 
macrophage accumulation and fibroblast activation. This interplay of 
angiogenesis, inflammation and fibrosis determines the extent of preservation 
and restoration of myocardial integrity.[2] In some circumstances, maladaptive 
persistent processes may encourage remodeling and scarring to extend into 
the myocardium long after the initial causative injury. This may lead to 
progressive ventricular dilatation, ventricular dysfunction and heart failure.  
 
The αvβ3  integrin is a trans-membrane cell surface receptor that facilitates 
migration, proliferation and interaction with the ECM, thereby allowing cells to 
respond to, and in turn modify, their extracellular environment. Expressed at 
low levels by quiescent endothelial cells, αvβ3 integrin is markedly up 



































































regulated in states of angiogenesis within the myocardium after infarction.[3,4] 
In addition, pre-clinical and clinical studies document αvβ3 integrin expression 
by both activated cardiac myofibroblasts and macrophages during 
margination and chemotaxis. Thus, αvβ3 integrin expression appears central to 
the co-ordination of repair following MI. 
 
In this study, we investigated the expression of αvβ3 integrin following MI using 
the novel αvβ3 integrin-selective radiotracer, 18F-fluciclatide, combined with 
cardiac positron emission tomography (PET), computed tomography (CT) and 
cardiovascular magnetic resonance (CMR). The study aims were to describe 
and characterize the uptake of this radiotracer, and to correlate it with clinical 









































































PET/CT scanning with 18F-fluciclatide and CMR were performed in 3 groups 
of participants recruited from Royal Infirmary of Edinburgh between July, 
2013, and February, 2015. Exclusion criteria were age <40 years, women of 
childbearing potential not taking contraception, severe renal failure (serum 
creatinine >2.8 mg/dL) or hepatic failure (Childs-Pugh grade B or C), atrial 
fibrillation, contrast allergy, inability to undergo scanning and inability to 
provide informed consent. Studies were performed with approval of the local 
research ethics committee, in accordance with the Declaration of Helsinki, 
and with the written informed consent of each participant. 
Study Participants  
Acute MI group. Patients with recent acute ST-segment elevation MI and peak 
high-sensitivity cardiac troponin I (hs-cTnI) >10,000 ng/L were invited to 
attend for PET/CT with 18F-fluciclatide 14±7 days after their initial 
presentation. CMR was performed within 7 days of PET/CT scanning. 
Patients were then invited to return for a second PET/CT with 18F-fluciclatide 
10 weeks after MI and for a follow-up CMR at 9 months. 
 
Chronic Total Occlusion (CTO) group. Patients with an angiographically-
documented complete occlusion of a major epicardial artery and stable 
cardiac symptoms for >6 months were invited to attend for a single PET/CT 
with 18F-fluciclatide and CMR. 
 



































































Control group. Volunteers with normal left ventricular systolic function, no 
structural heart disease, and no symptoms of heart failure or MI underwent a 
single PET/CT with 18F-fluciclatide and CMR. 
 
Histology Cohort 
For histological analysis, myocardial biopsy samples were obtained from 
patients undergoing coronary artery bypass grafting following recent MI. 
Patients with large ST-elevation MI (<14 days, hs-cTnI >10,000 ng/L) were 
considered for inclusion forming a separate cohort from the acute MI group. 
Radiosynthesis of 18F-Fluciclatide 
The radiotracer was manufactured at the Clinical Research Imaging Centre, 
University of Edinburgh on an automated module (FASTlab synthesizer; GE 
Healthcare) by coupling an amino-oxy-functionalized peptide precursor 
(AH111695) with 4-18F-fluorobenzaldehyde at pH 3.5 to form 18F-fluciclatide. 
Full description of this synthesis has been published.[5-7]  
Imaging Assessments 
All patients underwent PET-CT imaging of the thorax w th a hybrid scanner 
(Biograph mCT, Siemens Medical Systems, Germany) after administration of 
a target dose of 230 MBq 18F-fluciclatide (Supplementary Material). No 
dietary restrictions were required prior to radiotracer administration. 
Attenuation-correction CT scanning (non-enhanced 120 kV and 50 mA, 3-mm 
slices) was performed, followed by PET acquisition with electrocardiographic 
(ECG) gating. To assess tracer pharmacodynamics and the optimum timing of 
scanning, dynamic thoracic PET imaging was initially performed in 10 
subjects in 3-dimensional mode with a single bed position for 70 min. The 



































































remainder of study subjects underwent static imaging performed at the 
optimal time point as determined from the dynamic studies (40-min post-
injection) using a single 30-min bed position in list mode. Immediately after 
PET acquisition cardiac CT angiography was performed on the hybrid 
scanner (Supplementary Material). 
PET Reconstruction and Analysis 
Kinetic analysis of the dynamic scans was undertaken to investigate 18F-
fluciclatide uptake within the myocardium (Supplementary Material). For all 
patients, static ECG-gated PET images were reconstructed in diastole, 40-70 
min post-injection. Myocardial 18F-fluciclatide uptake was assessed by an 
experienced observer (WJ) by drawing regions of interest (ROI) in each 
myocardial segment using the standardized 16-segment approach [8]. 
Additionally, ROI’s were drawn in focal regions affected by infarction and in 
regions of remote myocardium. This was achieved using the fused CT 
angiography and CMR images as a reference, and with care taken to avoid 
contamination from the blood-pool signal. PET data were corrected for 
residual blood pool activity (standard uptake value, SUV) in the superior vena 
cava and expressed as a mean tissue-to-background ratio (TBRmean). SUVmax 
and TBRmax values were also calculated alongside the corrected SUV (SUVC) 





Cardiac CMR with assessment of late gadolinium enhancement (LGE) and T1 
mapping was performed at 3T (MAGNETOM Verio, Siemens AG, Healthcare 



































































Sector, Germany) with calculation of left ventricular function, wall motion index 
(WMI), transmurality of LGE, and extracellular volume fraction (ECV, 
Supplementary Material).  
Histology 
 
Briefly, a core cardiac biopsy was taken from the peri-infarct zone, fresh 
frozen and sectioned in cryosection medium (Supplementary Material). 
Adjacent tissue sections were stained with hematoxylin-eosin (HE) for 
conventional, smooth muscle actin, CD31, CD68 (clone PG-M1), and integrin 
αvβ3 antibody clone LM609 (Millipore) before digital imaging (Axioscan.Z1, 
Zeiss, UK) and histopathological examination 
Statistical Analysis 
 
We explored myocardial radiotracer uptake in 3 groups of patients, comparing 
them to CMR and clinical indices of cardiac function. Continuous data were 
tested for normality with the D’Agostino and Pearson Omnibus test.  
Continuous normal variables were expressed as mean±standard deviation 
and compared using Students t-testing or analysis of variance (ANOVA) 
testing when comparing more than 2 groups. Continuous non-normal 
variables were presented as median [interquartile range] and compared using 
the Mann-Whitney or Kruskal-Wallis test when evaluating two/more than two 
groups. Interobserver reproducibility was calculated by Bland-Altman method 
and presented as mean bias ±2 standard deviations, and intraclass 
correlation coefficients (ICC) with 95% confidence intervals (CI). The chi-
squared test was used for analysis of categorical variables. Univariable and 
multivariable logistic regression models were used to determine factors 



































































associated with an improvement in segmental myocardial function. Statistical 
analysis was performed with GraphPad Prism version 6 (GraphPad Software 
Inc., USA) and JMP version 10.0 (SAS Software, North Carolina, USA) where 
appropriate. A two-sided P-value<0.05 was considered statistically significant. 
  





































































Thirty-seven subjects underwent PET/CT after injection of 229±12 MBq 18F-
fluciclatide: 21 patients with acute MI, 7 patients in the CTO group and 9 
healthy volunteers (Tables 1 and 2). The groups were generally well balanced 
for age, sex and body-mass index. Healthy subjects had a lower prevalence 
of cardiovascular risk factors (Table 1). The mean radiation dose per 
participant for those who received a single PET/CT imaging assessment was 
13.6 (range 7.8-18.9) mSv, and 21.9 (range 16.5-28.7) mSv in those who 
underwent repeat PET scanning.  
 
CMR Characterisation of Myocardial Infarction & Remodeling 
There were no areas of infarction in control subjects. All patients within the 
acute MI cohort (n=21) had visible infarction on CMR 13±5 days after MI. 
These infarcts were large (infarct size 12±7 g/m2, peak cardiac troponin I 
50,000 [26,753-50,000] ng/L) and featured the anterior (n=16) and lateral 
(n=4) territories predominantly, while 1 patient had an inferior MI. All subjects 
received emergency coronary angiography with successful revascularization 
197 [148-342] min from the onset of symptoms (Table S1). 
 
Old infarcts were present in 6 of 7 patients in the CTO group. Although there 
was no difference in infarct size [g/m2] between MI and CTO groups (p=0.34), 
the left ventricular ejection fraction (LVEF) was reduced with a larger WMI 
score in those with recent MI (p<0.01 compared to either the CTO or control 
group, Table 2).  
 



































































Seventeen patients from the acute MI group received follow-up CMR imaging 
287±37 days after MI. During this timeframe, there were improvements in 
LVEF (p<0.01) and regional wall motion (WMI; p<0.005). In total, 43 of 272 
myocardial segments (16%) showed an improvement in regional wall motion, 
while 226 segments remained unchanged and 3 segments displayed 
functional deterioration. Infarct size and LV mass also improved (p=0.03 and 
p<0.01 respectively, Table 3). 
 
Histology & Dynamic Myocardial 18F-Fluciclatide PET 
 
In an exploratory analysis, 2 patients scheduled for coronary artery bypass 
surgery within 14 days of infarction underwent myocardial biopsies from the 
peri-infarct zone (Figure 1). This showed predominantly viable myocardium 
with widespread positive staining for αvβ3 integrin, largely in regions that co-
localized to CD31-positive vascular endothelial cells. Interestingly, these sites 
represented mainly angiogenic microvasculature, although there was 
scattered co-localisation with dual smooth muscle actin- and CD31-positive 
arterioles. There were lesser numbers of CD68-positive inflammatory cells 
and smooth muscle actin-positive myofibroblasts, but where present, they 
also co-registered with αvβ3 integrin expression (Figure 1).  
 
Dynamic PET studies were performed in a subgroup of 10 patients. 18F-
Fluciclatide activity within the region of myocardial infarction increased 
gradually and reached a plateau at around 30-40 min (Figure 2). The injected 
activity was cleared from the blood pool with a half-life of about 10 min, so 
that it remained relatively high during the period of PET acquisition (superior 



































































vena cava SUVmean 2.73±0.51 at 40-70 min post-injection). The optimum 
contrast between 18F-fluciclatide uptake in the site of infarction compared to 
the blood pool was observed at 40 min (Figure 2B). This time point was 
therefore used for subsequent static imaging.  
 
Using a 2-compartment Patlak model,[5] 18F-flucicatide uptake displayed a 
distinct linear phase and a steep Ki slope, in keeping with irreversible binding 
of 18F-fluciclatide to αvβ3 integrin during the 70-min period of evaluation 
(Figure 2D). The three-dimensional parametric images generated from Patlak 
analysis (Figure 2E, Figure 3F and Video 1) confirmed regions of increased 
18F-fluciclatide binding in sites of acute infarction, supporting an up-regulation 
of αvβ3 integrin within the infarct zone.  
 
Static 18F-Fluciclatide PET in Myocardial Infarction 
Using static PET images the interobserver reproducibility assessing 18F-
fluciclatide uptake in the myocardium was good (Table S2).  Briefly, 
quantifying focal uptake in acute infarction was most reproducible using the 
TBRmean method, showing no fixed or proportional biases (mean % difference 
3.0 [95% CI -24.0 to 29.9]) and a high ICC value (0.94 [95% CI 0.83-0.98]). 
This measure was therefore preferentially used for subsequent analysis. 
Quantification of the regional 18F-fluciclatide TBRmean in individual myocardial 
segments also proved reproducible with no fixed or proportional biases (mean 
% difference -8.97 [95% CI -31.6 to 13.6]) and a high ICC value (0.90 [95% CI 
0.590-0.975], Table S3). 



































































All patients in the acute MI cohort had increased focal myocardial uptake of 
18F-fluciclatide on baseline PET/CT scanning (12±4 days after MI), which co-
localized to regions of infarction on CMR (Figures 2 & 3, Tables 2 & 3, Videos 
1 & 2). Hepatic uptake of 18F-fluciclatide was common. However, in the 
patient with inferior MI, basal inferior and infero-septal myocardial uptake of 
18F-fluciclatide was quantifiable. 18F-Fluciclatide uptake was greater in the 
acute myocardial infarct when compared to regions of old infarction in the 
CTO cohort and healthy myocardium in the control group, regardless of the 
measure of PET uptake used (for example, TBRmean 1.34±0.22 vs. 0.70±0.14 
vs. 0.70±0.10, p<0.001 respectively). Indeed, no focal increase in 18F-
fluciclatide uptake was observed in regions of chronic infarction, with similar 
PET uptake measurements compared to control subjects (e.g. TBRmean, 
p=0.83). In regions of myocardium remote to the site of acute infarction, 18F-
fluciclatide activity was modestly but uniformly increased when compared to 
comparative regions in CTO patients (TBRmean 0.85±0.17 vs 0.64±0.12, 
p=0.009). Across our population there were no age-related (TBRmean, r=-0.19 
[-0.53-0.19], p=0.31) or sex-related (TBRmean 1.14±0.07 vs. 1.25±0.17, 
p=0.46) differences in 18F-fluciclatide uptake. 
 
Seventeen subjects agreed to return for a second 18F-fluciclatide PET/CT 
76±19 days post-MI, with similar results noted. All these patients were 
clinically stable between the scans. 18F-Fluciclatide uptake remained 
elevated at the site of infarction (MI vs. CTO group, TBRmean 1.20±0.21 vs. 
0.70±0.15 respectively, p<0.001), although the intensity was reduced 
compared to earlier imaging (p=0.01; Figure 3). Increased 18F-fluciclatide 



































































uptake also persisted in regions of remote myocardium when compared to 
uptake in CTO patients (TBRmean 0.82±0.15 vs 0.64±0.12 respectively, 
p=0.01) and interestingly remained equivalent in terms of intensity compared 
to the initial PET scan (TBRmean 0.85±0.17 vs 0.82±0.15 respectively, p=0.38). 
 
 
Myocardial 18F-Fluciclatide Uptake and Cardiac Function 
The extent of 18F-fluciclatide uptake following MI was compared with clinical 
and imaging measures of MI severity and subsequent repair (Table S3). 
Although segmental 18F-fluciclatide uptake displayed a moderate correlation 
with the degree of extracellular volume on CMR T1 mapping (r =0.37, 
p<0.001), it did not correlate with many of the standard measures of infarct 
severity, in particular there were no associations with infarct size on CMR 
(r=0.03, p=0.90), LVEF (r=-0.08, p=0.72), hs-TnI (r=0.13, p=0.36) or C-
reactive protein (r=-0.20, p=0.38) (Table S3). This may be explained by the 
absence of increased uptake in the largest akinetic infarcts (normal wall 
motion vs. akinetic segments; TBRmean 0.80±0.26 vs. 0.77±0.21, p=0.77). 
Rather 18F-fluciclatide activity was highest in segments with hypokinesis  
(WMI 1&2 vs. 0; TBRmean 0.92±0.03 vs 0.80±0.26, p<0.001; Figure 4) and 
segments associated with a subendocardial pattern of LGE (subendocardial 
LGE vs no LGE; TBRmean 0.95±0.06 vs. 0.75±0.03 respectively, p<0.001; 
Figure 4).  
 
18F-Fluciclatide uptake was higher in hypokinetic regions that subsequently 
demonstrated functional recovery compared to regions with no change or a 



































































worsening in contractile function (TBRmean 0.95±0.33 vs 0.81±0.02 
respectively, p=0.002; Figure 4, Video 2). Using logistic regression analysis, 
18F-fluciclatide TBRmean emerged as a predictor of recovery in segmental 
cardiac function on univariable analysis (OR 1.27 [95% CI 1.08-1.50] per 10% 
increase in TBRmean, p=0.003), which persisted after adjustment for age and 
sex (OR 1.27 [95% CI 1.07-1.51] per 10% increase in TBRmean, p=0.005). This 
effect was however attenuated following additional adjustment for the 
transmurality of LGE (OR 1.03 [95% CI 0.83-1.26] per 10% increase in 
TBRmean, p=0.80) and ECV (OR 1.02 [0.91-1.32] per 10% increase in 
TBRmean, p=0.35).   






































































Using the novel radiotracer 18F-fluciclatide, we have for the first time 
described the temporal expression of myocardial αvβ3 integrin receptor in 
patients with recent acute MI. We demonstrate intense early uptake 
attributable to regions of recent infarction, in particular subendocardial, 
hypokinetic infarcts that appeared to demonstrate subsequent functional 
recovery. Our data suggest that αvβ3 integrin receptor expression can be 
readily quantified in the infarct zone, and that 18F-fluciclatide PET may hold 
promise as a clinical biomarker of healing activity with application to novel 
pharmacological or cell-based therapies aimed at improving outcome after MI. 
 
Expression of αvβ3 integrin by vascular endothelial cells facilitates myocardial 
salvage through angiogenesis in the peri-infarct zone, while also mediating 
the activated macrophage response to inflammatory signals and governing 
myofibroblast differentiation through the activation of latent TGF-β1.[9-11] The 
αvβ3 integrin contains a binding site for an RGD-peptide subunit (the arginine-
glycine-aspartate motif) and this is the target for a number of molecular 
imaging probes. In murine and human studies of acute MI, RGD-based 
radiotracers accumulate at the site of infarction as early as 3 days, peaking at 
1-3 weeks post-MI [4,12] and correlating with adverse remodeling and infarct 
scar formation at 12 months.[13,14] For the first time, we have here confirmed 
and extended these findings using the highly selective and sensitive PET 
RGD-radiotracer, 18F-fluciclatide. Moreover, given the study sample size and 
comprehensive imaging assessment, we have been able to make several 



































































significant observations as well as incorporate a number of important controls 
and comparisons. 
 
We have compared 18F-fluciclatide uptake in patients with recent acute MI 
with healthy control subjects and patients with established infarction. We have 
demonstrated that 18F-fluciclatide uptake is specific for acute infarction and 
does not bind to old established infarcts. Perhaps more importantly, we did 
not see a correlation with acute infarct size, quantified as the mass of LGE on 
CMR. Indeed binding of 18F-fluciclatide in akinetic infarcts was relatively low, 
and was instead highest in sub-endocardial infarcts associated with 
hypokinesia. This would suggest that 18F-fluciclatide uptake is not a 
surrogate of infarction itself but relates more to the tissue healing response to 
injury.  
 
There are a number of potential explanations for the preferential binding of 
18F-fluciclatide to subendocardial infarcts. It is possible that microvascular 
obstruction in larger infarcts prevented tissue penetration by 18F-fluciclatide 
or that the presence of tissue necrosis resulted in loss of tissue architecture. 
However a number of our observations suggest that 18F-fluciclatide uptake 
reflects novel αvβ3 integrin expression due to re-endothelialisation and 
angiogenesis in the peri-infarct zone. First, ex-vivo histological examination 2 
weeks following MI demonstrated that αvβ3 integrin expression predominantly 
co-localizes within endothelial cells of the microvasculature. Second, 
increased 18F-fluciclatide uptake was associated with functional recovery of 
hypokinetic infarcts. Third, we did not observe 18F-fluciclatide uptake in 



































































patients with CTO who have chronic and well established collateral 
vasculature. Fourth we did not observe large regions of microvascular 
obstruction on CMR imaging. This suggests that only newly forming vessels 
or repopulation of vessels with endothelial cells will result in αvβ3 integrin 
expression and 18F-fluciclatide uptake. This is consistent with similar 
observations in other diseased states such as angiogenesis associated with 
malignancy.[5,7] In our patients with MI, intense binding was observed in the 
peri-infarct regions of sub-endocardial MIs with only poorly-defined uptake in 
the central necrotic area. Given these associations and the likelihood that 
18F-fluciclatide identifies areas of re-endothelialisation and angiogenesis, it is 
perhaps not surprising that 18F-fluciclatide uptake appeared to localise to 
segments that demonstrated subsequent functional recovery. Taken together 
our data suggest that assessing αvβ3 integrin expression in the acute phase of 
repair might be of use in investigating the healing processes that occur 
following acute MI. Larger studies are required to confirm these initial findings 
and assess whether 18F-fluciclatide PET provides incremental benefit to CMR 
(our study was not sufficiently powered). However as a marker of activity 18F-
fluciclatide may be of particular use in assessing the effects of novel therapies 
aimed at accelerating repair post-MI.  
 
At 10 weeks following MI, 18F-fluciclatide uptake persisted in the region of 
infarction but was reduced compared to the 2-week assessment. This delayed 
phase of repair is characterized pathologically by a reduction in inflammation 
and angiogenesis, and a more moderated reorganization of the ECM through 
myofibroblast-driven type I and III collagen production.[15] From our study, we 



































































are unable to determine whether this reduction in 18F-fluciclatide uptake 
reflects the waning of re-endothelialisation and angiogenesis, or represents a 
switching to myofibroblast cell types indicative of an enhanced fibrotic 
response. There was some heterogeneity in the time course of 18F-
fluciclatide uptake since uptake increased at 10 weeks in 6 subjects. 
However, we detected no adverse effects of this increase in uptake and there 
was no corresponding increase in LGE or ECV on T1 mapping. 
 
Modification of the extracellular matrix following MI is not only limited to the 
site of infarction. Indeed, the myofibroblast-driven fibrotic expansion seen in 
the remote myocardium influences global myocardial recovery.[16] 
Expression of αvβ3 integrin in remote myocardial regions has been reported up 
to 6 months following MI.[10,17] In keeping with this, 18F-fluciclatide activity 
was consistently increased in the remote myocardium at both 2 and 10 weeks 
when compared to comparative myocardial regions in patients with CTO, and 
healthy controls.  
 
There are some limitations of our study that we should acknowledge. First, 
despite accounting for systolic motion using electrocardiographic gating, 
cardiac PET is also limited by respiratory motion and this may affect 
sensitivity in particular due to the high activity in the closely adjacent blood 
pool and hepatic tissue. This is likely to be a particular problem for inferior 
infarcts (present in only one of our study subjects), although these less 
commonly lead to adverse remodelling and heart failure. Novel motion 
tracking may in the future help to negate some of these issues and enable 



































































even greater definition of regional αvβ3 integrin expression.[18] Second, 
limited cardiac tissue was available for histological assessment, preventing 
complete stoichiometric and temporal assessment of αvβ3 integrin expression 
in man post-MI. Fortunately inference can be drawn from extensive animal 
models of infarction, but for future application of 18F-fluciclatide a more 
extensive histological assessment would be preferred. Third, our study was 
not powered to address the incremental value of 18F-fluciclatide PET over 
established predictors markers of cardiac recovery such as CMR. This will 
require larger patient populations. Instead this study provides the first 
description of increased 18F-fluciclatide in the myocardium following MI, 
indicating that it provides important information about the LV remodeling 
response. Further studies will be required to establish the clinical utility of this 
approach. 
 
In conclusion, we report the largest and most comprehensive analysis of an 
αvβ3 integrin radiotracer in the assessment of myocardial repair following 
acute MI. We have demonstrated that increased 18F-fluciclatide uptake 
occurs at sites of acute myocardial infarction, in particular regions of sub-
endocardial infarction and hypokinesia associated with subsequent functional 
recovery. Our data suggest myocardial αvβ3 integrin expression represents a 
marker of ongoing cardiac repair, and that 18F-fluciclatide is a potentially 
useful imaging biomarker for investigating this healing response post-MI.  
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Figure 1. αvβ3 Integrin Expression in Patient with Recent 
Myocardial Infarction 
Adjacent fresh frozen and cryosectioned biopsies from the peri-infarct area of 
a patient with recent anterior MI. Immunohistochemical staining for (A) αvβ3 
integrin displayed multiple regions of positive staining that co-localize to 
regions of staining for vascular endothelial cells (CD31, B) visible at x4 
magnification. At x20 magnification, these regions of αvβ3 staining (C) 
correspond predominantly to arterioles and the microvasculature (D), and also 
to regions of staining for smooth muscle actin (E), representative of both 
arterioles (co-staining with CD31) and myofibroblasts. There were relatively 
few macrophages (F).  
Figure 2. Dynamic Analysis of 18F-Fluciclatide Uptake 
 
Axial and sagittal CT angiography of the thorax in a patient with recent 
anterior MI (A). The time-activity curves generated from the descending aorta 
and the apical interventricular septum (blue crosshairs) show increased 
uptake in the infarct relative to blood pool. Optimal contrast between 18F-
fluciclatide tissue and blood pool activity was observed after 40 min (dotted 
line, B). The PET image in the axial and sagittal plane shows increased 
uptake within the apical septum, although there is some background activity 
(C). Patlak analysis of ROI’s placed in the interventricular septum confirms 
integrin binding, as evidenced by the gradient of the slope and the y-intercept 
(D), and using a Ki-generated image we can better identify and delineate focal 
uptake within myocardium (E). A region of remote myocardium within the 



































































same patient generates a Patlak curve with significantly lower gradient and 
intercept in comparison (F).  
Figure 3. 18F-Fluciclatide Uptake in Acute Myocardial Infarction 
 
18F-Fluciclatide uptake in 3 patients with recent subendocardial myocardial 
infarction (MI). Patient 1, 13 days after anterior MI, displaying a short-axis 
PET image of the left ventricle with crescentric 18F-fluciclatide uptake (A) that 
correlates with the interventricular septum and anterior wall on CT 
angiography (B). The fused PET/CT-angiography image (C) shows this 
uptake corresponds exactly to the region of late gadolinium enhancement 
(LGE) on CMR (D). Further delineation of myocardial uptake on PET/CT is 
clearer in the 2-chamber view (E) and on a fused CT/3D-Patlak image, which 
shows this uptake to follow a watershed-pattern emerging from the coronary 
stents present in the left anterior descending coronary artery (F) (see Video 
File 1). Panels G & H: patient 2, 8 days following anterior MI, displaying focal 
uptake of 18F-fluciclatide in the anterior wall and apex in the 3-chamber view 
on PET/CT (G) which corresponds to the region of infarction on LGE CMR 
imaging (H). Panels I & J: patient 3, showing focal uptake of 18F-fluciclatide 
in the inferior wall 19 days following MI on PET/CT (I) that again corresponds 
to the infarction on CMR LGE imaging (J).  
Figure 4. 18F-Fluciclatide Uptake in Myocardial Infarction 
 
Uptake of 18F-fluciclatide in (A) patients with acute myocardial infarction at 2 
and 10 weeks, patients with chronic total occlusion and healthy control 
subjects. Uptake was greatest at 2 weeks after myocardial infarction (B). 18F-
Fluciclatide uptake in the acute MI group was greater in regions of 



































































hypokinesis when compared to sites of normal function or akinesis (C). This 
translated to a higher 18F-fluciclatide uptake in those regions which 
subsequently improved in function on follow-up CMR (D). 
  




























































































Patient Characteristics      
Age (years) 64±10 62±12 69±7 66±7 0.06 
Male Sex 27(73) 16(76) 5(71) 6(67) 0.46 
BMI (kg/m
2
) 28±4 28±5 31±3 27±4 0.74 
18F-Fluciclatide Dose (mBq) 229±12 227±13 227±14 232±9 0.86 
Current Smoker 9(24) 8(38) 1(14) 0(0) 0.01 
Diabetes Mellitus 4(11) 3(14) 1(14) 0(0) 0.06 
Hypertension 16(43) 7(33) 5(71) 4(44) 0.04 
Hypercholesterolemia 22(60) 14(66) 6(86) 2(22) <0.001 
Cardiovascular History 
Prior myocardial infarction 7(19) 1(5) 6(86) 0(0) <0.001 
Angiographically 
documented CAD 
28(76) 21(100) 7(100) 0(0) <0.001 
Previous PCI 4(11) 1(5) 3(42) 0(0) <0.001 
CCS Class 
0 28(76) 17(81) 2(29) 9(100) 0.02 
I or II 7(19) 4(19) 3(42) 0(0) 0.03 
III or IV 2(6) 0(0) 2(29) 0(0) 0.51 
NYHA Class 
I 29(78) 15(71) 3(42) 9(100) 0.32 
II 7(19) 5(24) 2(29) 0(0) 0.39 
III or IV 2(6) 1(5) 1(14) 0(0) 0.25 
Medications 
Aspirin 27(73) 21(100) 6 (86) 0(0) <0.001 
Clopidogrel 22(59) 19(90) 3(42) 0(0) <0.001 
Statin 29(78) 21(100) 7(100) 1(11) 0.004 
β-Blocker 26(70) 20(95) 6(86) 0(0) <0.001 
ACEi / ARB 27(73) 20(95) 5(71) 2(22) 0.02 
Clinical Features 
Systolic BP (mm Hg) 137±22 128±18 140±24 155±21 0.06 
Heart rate (bpm) 64±12 62±13 61±11 68±10 0.42 
Creatinine (µmol/L) 79±15 82±19 77±14 73±12 0.54 
hs-CRP (mg/L) 3.5[1.3-9.8] 5.6[2.0-11.7] 2.2[1.0-9.1] 1.5[1.2-3.3] 0.008 




































































Mean±SD, median [IQR] or number (percentage). *Analysis of variance, Students t-test 
(continuous data) or Chi squared test (categorical data). 
 
Abbreviations: BMI, body-mass index; CAD, coronary artery disease; PCI, percutaneous 
coronary intervention; CCS, Canadian Cardiovascular Society; NYHA, New York Heart 
Association; ACEi, angiotensin-converting enzyme inhibitor, ARB, angiotensin receptor 
blocker; BP, blood pressure; hs-CRP, high-sensitivity c-reactive protein 
 
  



























































































CMR Imaging  
LVEF (%) 58±10 52±9 62±8 65±5 <0.001 
LV Mass (indexed,g/m
2
) 79±20 85±20 66±17 75±16 0.07 
LVEDV (mL/m
2
) 77±18 80±18 69±13 76±17 0.35 
LVESV (mL/m
2
) 34±13 39±14 30±10 27±9 0.046 
WMI  0.25±0.13 0.40±0.20 0.09±0.05 0.0±0.0 <0.001 
ECV (%) 31±5 34±4 28±3 28±2 <0.001 
Presence of LGE 27(73) 21(100) 6(86) 0(0) <0.001 
Infarct size (g/m
2
) 8±8 12±7 8±8 0±0 <0.001 
PET Imaging  
SUVmean (kBq/mL)  
     SVC  2.73±0.51 2.85±0.51 2.57±0.39 2.58±0.57 0.27 
     Total LV uptake 2.24±0.51 2.33±0.48 1.96±0.53 1.77±0.27 <0.001 
     Myocardial Infarct Uptake  3.23±1.03 3.72±0.63 1.76±0.26 - <0.001 
     Remote Myocardial Uptake  2.21±0.60 2.41±0.57 1.62±0.14 - 0.001 
TBRmean   
     Total LV Uptake 0.77±0.16 0.82±0.18 0.71±0.06 0.70±0.03 0.08 
     Myocardial Infarct Uptake 1.05±0.37 1.34±0.22 0.70±0.14 - <0.001 
     Remote Myocardial Uptake 0.80±0.18 0.85±0.17 0.64±0.12 - 0.009 
SUVmax  (kBq/mL)  
     Total LV uptake 2.71±0.58 2.86±0.56 2.24±0.40 2.07±0.31 <0.001 
     Myocardial Infarct Uptake 3.53±1.00 3.98±0.68 2.18±0.35 - <0.001 
     Remote Myocardial Uptake 2.59±0.64 2.75±0.65 2.18±0.35 - 0.02 
TBRmax  
     Total LV uptake 0.98±0.19 1.02±0.19 0.89±0.20 0.81±0.09 0.01 
     Myocardial Infarct Uptake 1.28±0.34 1.42±0.25 0.86±0.16 - <0.001 
     Remote Myocardial Uptake 0.94±0.19 0.97±0.20 0.84±0.13 - 0.11 
SUVC (kBq/mL)  
     Total LV uptake  -0.55±0.57 -0.52±0.55 -0.61±0.67 0.81±0.42 0.85 
     Myocardial Infarct Uptake 0.75±0.91 1.13±0.67 -0.40±0.46 - <0.001 
     Remote Myocardial Uptake -0.19±0.52 -0.11±0.54 -0.45±0.37 - 0.12 
 
 



































































Mean±SD or number (percentage). *Analysis of variance, Students t-test (continuous data) or 
Chi squared test (categorical data). 
 
 
Abbreviations: CMR,cardiac magnetic resonance; LVEF,left ventricular ejection fraction; 
LVEDV,left ventricular end diastolic volume; LVESV,left ventricular end systolic volume; 
WMI,wall motion index; ECV,extracellular volume; LGE,late gadolinium enhancement; SVC; 
superior vena cava; SUV,standardized uptake value; TBR,tissue-to-background ratio, SUVC, 
corrected SUV  




































































Acute myocardial infarction assessments   
 
CMR Imaging Imaging Data p-value 





MI to CMR (days) 13±5 287±37 <0.01 
LVEF (%) 52±9 55±8 <0.01 
Indexed LV Mass (g/m
2
) 85±20 74±13 <0.01 
LVEDV (mL/m
2
) 80±18 82±16 0.88 
LVESV (mL/m
2
) 39±14 38±12 0.36 
Wall Motion Index 0.40±0.20 0.22±0.15  <0.01 
ECV (%) 34±4 33±2 0.58 
Infarct size (g/m
2
) 13 [7-17] 6 [3-14] 0.03 
 
PET Imaging 





MI to PET (days) 12±4 76±19 <0.01 
Total LV Uptake (TBRmean) 0.82±0.18 0.85±0.18 0.96 
Myocardial Infarct Uptake (TBRmean) 1.34±0.22 1.20±0.21 0.02 
Remote Myocardial Uptake (TBRmean) 0.85±0.17 0.82±0.15 0.38 
Segmental uptake (TBRmean) & Regional Wall Motion (WMI)  
      Normal function (0) 0.80±0.26 0.83±0.23 0.14 
      Mild-mod hypokinesia (1) 0.89±0.33 0.97±0.29 0.33 
      Severe hypokinesia (2) 0.97±0.28 0.91±0.34 0.47 
      Akinesia (3) 0.77±0.21 0.73±0.24 0.66 
      Dyskinesia (4) - - - 
Segmental uptake & Transmurality of MI (TBRmean) 
     No infarct 0.75±0.23 0.81±0.23 NA 
     Subendocardial infarct (1-75%) 0.95±0.29 1.08±0.28 NA 
     Transmural infarct (76-100%) 0.89±0.29 0.88±0.27 NA 
 
Mean±SD or median [IQR].  
 
Abbreviations: MI, myocardial infarction; LV, left ventricle; TBRmean, mean tissue-to-
background ratio; CMR, magnetic resonance imaging; LVEF, left-ventricular ejection fraction; 
LVEDV, left-ventricular end diastolic volume; LVESV, left ventricular end systolic volume; 
WMI, wall motion index; ECV, mean extracellular volume.  





































































Figure 1. αvβ3 Integrin Expression in Patient with Recent Myocardial Infarction. Adjacent fresh frozen and 
cryosectioned biopsies from the peri-infarct area of a patient with recent anterior MI. Immunohistochemical 
staining for (A) αvβ3 integrin displayed multiple regions of positive staining that co-localize to regions of 
staining for vascular endothelial cells (CD31, B) visible at x4 magnification. At x20 magnification, these 
regions of αvβ3 staining (C) correspond predominantly to arterioles and the microvasculature (D), and also 
to regions of staining for smooth muscle actin (E), representative of both arterioles (co-staining with CD31) 
and myofibroblasts. There were relatively few macrophages (F).  
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Figure 2. Dynamic Analysis of 18F-Fluciclatide Uptake. Axial and sagittal CT angiography of the thorax in a 
patient with recent anterior MI (A). The time-activity curves generated from the descending aorta and the 
apical interventricular septum (blue crosshairs) show increased uptake in the infarct relative to blood pool. 
Optimal contrast between 18F-fluciclatide tissue and blood pool activity was observed after 40 min (dotted 
line, B). The PET image in the axial and sagittal plane shows increased uptake within the apical septum, 
although there is some background activity (C). Patlak analysis of ROI’s placed in the interventricular 
septum confirms integrin binding, as evidenced by the gradient of the slope and the y-intercept (D), and 
using a Ki-generated image we can better identify and delineate focal uptake within myocardium (E). A 
region of remote myocardium within the same patient generates a Patlak curve with significantly lower 
gradient and intercept in comparison (F).  
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Figure 3. 18F-Fluciclatide Uptake in Acute Myocardial Infarction. 18F-Fluciclatide uptake in 3 patients with 
recent subendocardial myocardial infarction (MI). Patient 1, 13 days after anterior MI, displaying a short-
axis PET image of the left ventricle with crescentric 18F-fluciclatide uptake (A) that correlates with the 
interventricular septum and anterior wall on CT angiography (B). The fused PET/CT-angiography image (C) 
shows this uptake corresponds exactly to the region of late gadolinium enhancement (LGE) on CMR (D). 
Further delineation of myocardial uptake on PET/CT is clearer in the 2-chamber view (E) and on a fused 
CT/3D-Patlak image, which shows this uptake to follow a watershed-pattern emerging from the coronary 
stents present in the left anterior descending coronary artery (F) (see Video File 1). Panels G & H: patient 2, 
8 days following anterior MI, displaying focal uptake of 18F-fluciclatide in the anterior wall and apex in the 
3-chamber view on PET/CT (G) which corresponds to the region of infarction on LGE CMR imaging (H). 
Panels I & J: patient 3, showing focal uptake of 18F-fluciclatide in the inferior wall 19 days following MI on 
PET/CT (I) that again corresponds to the infarction on CMR LGE imaging (J).  
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Figure 4. 18F-Fluciclatide Uptake in Myocardial Infarction. Uptake of 18F-fluciclatide in (A) patients with 
acute myocardial infarction at 2 and 10 weeks, patients with chronic total occlusion and healthy control 
subjects. Uptake was greatest at 2 weeks after myocardial infarction (B). 18F-Fluciclatide uptake in the 
acute MI group was greater in regions of hypokinesis when compared to sites of normal function or akinesis 
(C). This translated to a higher 18F-fluciclatide uptake in those regions which subsequently improved in 
function on follow-up CMR (D).  
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Positron Emission Tomography / Computer Tomography Imaging 
 
All patients underwent PET-CT imaging of the thorax with a hybrid scanner (Biograph 
mCT, Siemens Medical Systems, Erlangen, Germany) at the Clinical Research Imaging 
Centre, University of Edinburgh. Subjects were administered a target dose of 230 MBq 
18F-fluciclatide. An attenuation-correction CT scan (non-enhanced 120 kV and 50 mA, 
3-mm slices) was performed, followed by the PET acquisition with electrocardiographic 
(ECG) gating. To assess tracer pharmacodynamics and the optimum timing of 
scanning, dynamic PET imaging of the thorax was initially performed in 10 subjects in 3-
dimensional mode with a single bed position for 70 min. The remainder of study 
subjects underwent static imaging performed at the optimal time point (40 min post-
injection) using a single 30-min bed position in list mode. To enable an accurate 
definition of cardiac anatomy cardiac CT angiography was performed on the hybrid 
scanner immediately after the PET acquisition: 330 ms rotation time, 100 (body mass 
index <25 kg/m2) or 120 (body mass index >25 kg/m2) kV tube voltage, 160-245 mAs 
tube current, 3.8 mm/rotation table feed, prospective (heart rate regular and <60 /min), 
or retrospective (heart rate >60 /min) electrocardiogram-gated. Depending on the body 
mass index, a bolus of 80-100 mL contrast (400 mgI/mL; Iomeron, Bracco, Milan, Italy) 
was injected intravenously at 5 mL/s, after determining the appropriate trigger delay with 
a test bolus of 20 mL contrast material.  



































































PET Kinetic Analysis 
Kinetic analysis was undertaken to investigate the uptake of 18F-fluciclatide within the 
myocardium. The dynamic PET data were reconstructed (Ultra-HD, 2 iterations, 21 
subsets, 256 pixels, 1.6-mm pixel size) using a dynamic protocol without ECG gating in 
following time frames; 60s x 5, 120s x 5, 180s x 5, 300s x 8. Regions of interest (ROI’s) 
were drawn in the d scending aorta blood pool and myocardium, and used to derive 
time activity curves after decay correction. An input function calculation based on the 
PET image–derived activity curve from the aorta blood pool [1] and the myocardial time-
activity curve were used to estimate the tissue influx rate Ki (the slope of the linear 
regression) and the volume of distribution (the y-axis intercept) using a 2-tissue 
irreversible Patlak model [2,3]. Thoracic 18F-fluciclatide dynamic activity was then 
normalized for the blood-pool input function on a voxel-by-voxel basis, and after 3D 
Gaussian filtering (5-mm FWHM) a parametric 3-dimensional image of 18F-fluciclatide 
uptake was generated (PMod version 3.409, Pmod technologies limited, Switzerland). 
Using this image, regions of 18F-fluciclatide binding in the myocardium were identified 
and manually delineated for subsequent Ki analysis.  
 
Static Image Reconstruction and Analysis 
 
For all patients, static ECG-gated PET images were reconstructed in diastole (40-70 
min post-injection, 50–75% of the R-R interval, Ultra-HD, 2 iterations, 24 subsets, zoom 
x2, 200 pixels). Images were analysed by an experienced observer (WJ) using an 
OsiriX workstation (OsiriX version 6.0 64-bit; OsiriX Imaging Software, Geneva, 


































































Switzerland). PET images were fused and aligned with CT angiography datasets in 
diastole. Myocardial radiotracer uptake was quantified using two methods. First, using a 
standardized approach PET/CT datasets were re-orientated into traditional short-axis, 
2-chamber, 3-chamber and 4-chamber views with a slice thickness of 3 mm in order to 
fully visualize myocardial radiotracer uptake and allow comparison with CMR imaging. 
Regions of interest (ROIs) were drawn at sites that corresponded to the areas of acute 
infarction seen on CMR late gadolinium enhancement imaging. To define referent 
‘remote’ myocardial regions, ROI’s were drawn within proximal regions of the 
myocardial territory that displayed no CMR evidence of infarction. Care was taken to 
avoid blood-pool contamination. ROIs were copied onto the PET dataset and mean 
radiotracer activity measured using standard uptake values (SUV; the decay corrected 
tissue concentration of the tracer divided by the injected dose per body weight) and 
corrected for radiotracer blood-pool activity in the superior vena cava (SVC) to provide a 
mean tissue-to-background ratio (TBRmean).[4,5] Second, the CT angiography dataset 
was re-orientated into the left ventricular short axis (slice thickness 8 mm). Basal, mid-
cavity, and apical regions were manually delineated into segmental ROI’s according to 
the standard 17-segment model recommended by the American College of 
Cardiology/American Heart Association.[6] We excluded the true apex as it was not 
possible to avoid partial volume effects. ROI’s were then copied onto the re-orientated 
PET image dataset and segmental SUV and TBR data extracted using the technique 
above. In a substudy of 10 randomly selected subjects, interobserver reproducibility was 
assessed by two experienced observers (WJ,CM). 
 






































































Cardiac MRI was performed at 3 T (MAGNETOM Verio, Siemens AG, Healthcare 
Sector, Erlangen, Germany). For the assessment of left ventricular function, short-axis 
cine images from the mitral valve annulus to the apex were obtained using a balanced 
steady-state free-precession sequence (8-mm parallel slices with 2-mm spacing). 
Quantification of left ventricular function and volumes indexed to body surface area was 
assessed with dedicated software (Siemens AG Healthcare Sector, Erlangen, 
Germany). Regional systolic function assessments were performed from the basal, mid, 
and apical short-axis slices by calculating the end-diastolic and end-systolic wall 
thicknesses and expressed as the wall motion score index (WMSI; 0, normal; 1, mild or 
moderate hypokinesia; 2, severe hypokinesia; 3, akinesia; 4, dyskinesia).[7] The 
assessment of focal replacement myocardial fibrosis was performed with late 
gadolinium enhancement (LGE) imaging, 15 min after administration of 0.1 mmol/kg 
gadobutrol (Gadovist/Gadavist, Bayer Pharma AG, Berlin, Germany). An inversion 
recovery fast gradient-echo sequence was applied to the left ventricular short-axis stack 
with the inversion time optimized to achieve satisfactory nulling of the myocardium. The 
amount of LGE was quantified with QMASS software (Medis Medical Imaging Systems, 
Leiden, the Netherlands) using a signal intensity threshold greater than twice the 
standard deviation above the mean value in a normal region of myocardium sampled on 
the same short-axis image. The transmural extent of infarction within each segment was 
classified using a transmurality score (transmurality index; 0, no LGE; 1, 1-50%; 2, 51-
75% or 3, 76-100%) and recorded as either subendocardial (1-2) or transmural (3).[8] 


































































Areas thought to represent inversion artefact or blood pool contamination were 
manually excluded. Myocardial extracellular volume fraction (ECV) has been 
demonstrated to act as a measure of myocardial fibrosis in a variety of cardiac 
conditions.[9,10] Recently, our group has described a highly reproducible standardized 
approach to analyze myocardial ECV. [11] Briefly, myocardial T1 mapping was 
performed in the mechanism cohort using the modified look-locker inversion recovery 
sequence: flip angle, 35°; minimum TI, 100 ms; TI increment, 80 ms; and time delay, 
150 ms with a heartbeat acquisition scheme of 3-3-5. [12] Regions of interest were 
drawn around the myocardium on the short-axis, pre-contrast, motion-corrected 
myocardial T1 maps and copied onto corresponding 20-min post-contrast maps, with 
minor adjustments made to avoid partial volume effects and artifact (OsiriX version 
4.1.1, Geneva, Switzerland). ECV was calculated according to the following formula: 
ECV=(∆R1myocardium/∆R1blood-pool) ×(1−hematocrit) 
 where: 
∆R1=(1/postcontrast T1−1/precontrast T1). 
 




For histological analysis, myocardial biopsy samples were obtained from patients 
undergoing coronary artery bypass grafting following myocardial infarction. Patients with 
recent large ST-elevation myocardial infarction (<14 days, hs-cTnI >10,000 ng/L) were 
considered for inclusion. A core cardiac biopsy was taken intra-operatively under direct 


































































visualisation by an experienced surgeon from the peri-infarct zone. Samples were fresh 
frozen and mounted in cryosection medium. The tissue samples were then cut in 
sequential, longitudinal 4-µm sections at -20 °C and thaw-mounted onto microscope 
slides. They were dried for 15 min and spray-fixed with neutral buffered formalin. After 
rinsing in distilled water, sections were stained with hematoxylin-eosin (HE) and van-
Gieson (VG) for conventional histopathological examination. In order to optimize 
immunohistochemistry, an antigen-unmasking step was performed by microwave 
treatment for 30 s. Endogenous peroxidase was blocked by incubation with hydrogen 
peroxide for 5 min. Sections were subsequently incubated with the primary antibodies; 
smooth muscle actin, CD31, CD68 (clone PG-M1), and integrin αvβ3 antibody, clone 
LM609 (Millipore) for 30 min at room temperature. After washing the sections were 
incubated with Envision Flex (DAKO, K5007) for 30 min at room temperature, followed 
by incubation with diaminobenzamine (Sigma) for 10 min. The slides were finally 
counterstained with hematoxylin and digitally imaged (Axioscan.Z1, Zeiss, UK) before 
assessment. 
PET Repeatability Studies 
 
The reproducibility of 18F-fluciclatide uptake quantification was assessed in both the 
blood pool and the myocardium in 10 subjects selected at random. Residual blood pool 
radiotracer activity was quantified within both the SVC and right atrium. Whi le both 
methods displayed no fixed or proportional biases with narrow limits of agreement and 
high ICC values of >0.94, the SVC-approach appeared to hold a slight advantage (ICC 
0.97 [95% CI; 0.93-0.99]) and this therefore was applied throughout the study to 
quantify latent radiotracer blood activity (supplementary table 1).  Quantification of 


































































radiotracer uptake within the region of myocardial infarction was assessed using the 
mean Standard Uptake Value (SUVmean), the mean tissue to background ratio (TBRmean) 
and a novel method subtracting the target tissue mean SUV from the blood pool mean 
SUV (SUVtarget – blood pool).[14] The SUVmean and TBRmean both proved highly reproducible, 
displaying no fixed or proportional biases (mean % difference [95% limits of agreement]; 
3.0 [-27.2 - 33.3], and 3.0 [-24.0-29.9] respectively) and a high ICC value (0.93 [0.82-
0.97] and 0.940 [0.83-0.98] respectively). Selecting repeatable regions of remote 
myocardium proved less reliable, with wider limits of agreement (-18.9-66.2) and a 
moderate intra-class coefficient value of 0.60. The TBRmean method was selected for the 
study to compensate for potential contamination from residual blood pool activity.  
 
To quantify segmental myocardial uptake, a 16-segment model approach using both the 
TBRmean the SUVmean quantification methods appeared reliable, again with no fixed or 
proportional bias and reasonable limits of agreement (mean % difference, -8.97 [-31.6-
13.6] and -6.7 [-25.3-11.9], respectively) and an excellent ICC of 0.90 and 0.96 
respectively (Table 1). The TBRmean approach was selected for the study again to 
compensate for potential blood pool contamination,    
 
  


































































Supplementary Table 1. Characteristics of patients with acute myocardial 
infarction 
 
Clinical Data Acute MI Group 
(n=21) 
Peak cardiac troponin I (ng/L) 50,000 [26,753-50,000] 
Percutaneous coronary intervention 20 (95) 
Symptom onset to reperfusion (min) 197 [148-342] 
Single vessel disease 10 (48) 
Myocardial Infarction Territory  
        Anterior 16 (76) 
        Lateral 4 (19) 
        Inferior 1 (5) 
Adverse Outcome 
        TIMI Flow post-PCI <3 1 (5) 
        Cardiogenic Shock 3 (14) 
        IABP 2 (10) 
        Aborted cardiac arrest 2 (10) 
 
Median [interquartile range] and number (%). 
Abbreviations; TIMI, trials in myocardial infarction; PCI, percutaneous coronary intervention; 
IABO, intra-aortic balloon pulsation 
  


































































Supplementary Table 2. 18F-Fluciclatide Reproducibility  
 
 Reproducibility Analysis 
 Mean % differencea Intra-class coefficientb 
Blood pool assessment (SUV)   
SVC 3.1 (-9.5–15.6) 0.971 (0.928-0.989) 
Right Atrium -0.46 (-11.7-10.7) 0.943 (0.868-0.975) 
Infarct assessment    
TBRmean 
Whole Ventricle  -8.97 (-31.6-13.6) 0.898 (0.590-0.975) 
Infarct 3.0 (-24.0-29.9) 0.940 (0.833-0.978) 
Remote myocardium 23.7 (-18.9-66.2) 0.604 (-0.280-0.847) 
SUVmean   
Whole ventricle technique -6.7 (-25.3–11.9) 0.957 (0.830-0.989) 
Infarct 3.0 (-27.2-33.3) 0.930 (0.819-0.973) 
Remote myocardium  21.2 (-11.1-53.7) 0.787 (0.448-0.918) 
Infarct:remote myocardium ratio -18.2 (-60.6-24.1) 0.687 (0.187-0.879) 
SUVtarget tissue - blood pool   
Whole Ventricle 24.1 (-19.2–67.3) 0.410 (-0.372-0.698) 
Infarct  77.7 (-464.6–620.1) 0.933 (0.814-0.976) 
Remote Myocardium -43.8 (-120.4-32.7) 0.574 (-0.106-0.836) 
 
a Mean % difference between standard uptake value (SUV; kBq/mL) measurements (95% limits of 
agreement), and b ICC (intraclass correlation coefficient) values (95% confidence intervals) for 18F-
fluciclatide myocardial uptake and residual blood pool activity.  
SVC, superior vena cava; TBRmean, mean tissue to background ratio. 
 
  


































































Supplementary Table 3; Comparison of 18F-Fluciclatide Uptake and Indices of 
Infarction 
 
Ψ ECV and PET association assessed per segment. Abbreviations: hs-cTnI, high sensitivity cardiac 
troponin I; hs-CRP, high sensitivity c-reactive protein; LVEF, left ventricular ejection fraction; LV, left 






Infarct uptake  
(1st-2nd scan,TBRmean) 
Mean ECV (%) Infarct Size 
(g/m2) 
Clinical Characteristics 
























Baseline CMR Assessment 









































Follow-up CMR Assessment (9 months) 
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